Skip to Main Content
Phase II

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/​A011-16) (CADENCE)

  • Study HIC#:2000032349
  • Last Updated:03/25/2024

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.

The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

  • Age18 years - 85 years
  • GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Anna Hessler

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

Trial Purpose and Description

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.

The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

Eligibility Criteria

Individuals aged 18-85 who have been diagnosed with HFpEF and Cpc-PH.

Principal Investigator

Sub-Investigator

For more information about this study, including how to volunteer, contact: